-
公开(公告)号:US20070010524A1
公开(公告)日:2007-01-11
申请号:US11474132
申请日:2006-06-22
申请人: Penglie Zhang , Andrew Pennell , John J. Wright , Wei Chen , Manmohan Leleti , Yandong Li , Lianfa Li , Yuan Xu
发明人: Penglie Zhang , Andrew Pennell , John J. Wright , Wei Chen , Manmohan Leleti , Yandong Li , Lianfa Li , Yuan Xu
IPC分类号: A61K31/496 , A61K31/519 , C07D487/02 , C07D403/02
CPC分类号: C07D487/04 , C07D471/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常为芳基哌嗪衍生物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US20070010523A1
公开(公告)日:2007-01-11
申请号:US11474130
申请日:2006-06-22
申请人: Penglie Zhang , Andrew Pennell , John J. Wright , Wei Chen , Manmohan Leleti , Matthew Ronsheim
发明人: Penglie Zhang , Andrew Pennell , John J. Wright , Wei Chen , Manmohan Leleti , Matthew Ronsheim
IPC分类号: A61K31/519 , C07D487/02
CPC分类号: C07D487/04 , C07D471/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
-
公开(公告)号:US20070066583A1
公开(公告)日:2007-03-22
申请号:US11504215
申请日:2006-08-14
申请人: Penglie Zhang , Andrew Pennell , John J. Wright , Lianfa Li , Edward Sullivan , Wei Chen , Kevin Lloyd Greenman
发明人: Penglie Zhang , Andrew Pennell , John J. Wright , Lianfa Li , Edward Sullivan , Wei Chen , Kevin Lloyd Greenman
IPC分类号: A61K31/55 , A61K31/506 , A61K31/541 , A61K31/5377 , A61K31/496 , A61K31/454 , C07D417/02 , C07D413/02 , C07D403/02
CPC分类号: C07D413/06 , C07D231/56 , C07D233/36 , C07D235/26 , C07D263/22 , C07D263/58 , C07D265/18 , C07D295/185 , C07D401/06 , C07D413/04 , C07D471/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常是单环和双环化合物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US07741519B2
公开(公告)日:2010-06-22
申请号:US12024860
申请日:2008-02-01
申请人: Solomon Ungashe , Zheng Wei , John J. Wright , Andrew Pennell , Brett Permack , Thomas Schall
发明人: Solomon Ungashe , Zheng Wei , John J. Wright , Andrew Pennell , Brett Permack , Thomas Schall
IPC分类号: C07C303/00 , A61K31/33 , A61K31/55 , A61K31/397
CPC分类号: C07D213/26 , A61K31/4245 , A61K31/433 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
摘要翻译: 提供了作为趋化因子受体的有效拮抗剂的化合物。 化合物通常为芳基磺酰胺衍生物,可用于药物组合物,治疗趋化因子受体介导的疾病的方法,以及用于鉴定趋化因子拮抗剂的测定中的对照。
-
公开(公告)号:US07582661B2
公开(公告)日:2009-09-01
申请号:US11046565
申请日:2005-01-27
申请人: Solomon Ugashe , Zheng Wei , John J. Wright , Andrew Pennell
发明人: Solomon Ugashe , Zheng Wei , John J. Wright , Andrew Pennell
IPC分类号: A61K31/4425 , C07D213/20
CPC分类号: C07C311/29 , C07C311/21 , C07C311/46 , C07C317/14 , C07D213/26 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
摘要翻译: 提供了作为CCR9受体的有效拮抗剂的化合物,并且已经在用于CCR9的标志性疾病状态之一的炎症的动物试验中进一步证实了这些化合物。 化合物通常为芳基磺酰胺衍生物,并且可用于药物组合物,用于治疗CCR9介导的疾病的方法,以及用于鉴定CCR9拮抗剂的测定中的对照。
-
公开(公告)号:US08642808B2
公开(公告)日:2014-02-04
申请号:US13092615
申请日:2011-04-22
申请人: Solomon Ungashe , Zheng Wei , John J. Wright , Andrew Pennell , Brett Permack , Thomas Schall
发明人: Solomon Ungashe , Zheng Wei , John J. Wright , Andrew Pennell , Brett Permack , Thomas Schall
IPC分类号: C07C303/00 , A61K31/33 , A61K31/35 , A61K31/397
CPC分类号: C07D213/26 , A61K31/4245 , A61K31/433 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
摘要翻译: 提供了作为趋化因子受体的有效拮抗剂的化合物。 化合物通常为芳基磺酰胺衍生物,可用于药物组合物,治疗趋化因子受体介导的疾病的方法,以及用于鉴定趋化因子拮抗剂的测定中的对照。
-
公开(公告)号:US07335653B2
公开(公告)日:2008-02-26
申请号:US11789304
申请日:2007-04-23
申请人: Solomon Ungashe , Zheng Wei , John J. Wright , Andrew Pennell , Brett Permack , Thomas Schall
发明人: Solomon Ungashe , Zheng Wei , John J. Wright , Andrew Pennell , Brett Permack , Thomas Schall
IPC分类号: A61K31/54
CPC分类号: C07D213/26 , A61K31/18 , A61K31/195 , A61K31/397 , A61K31/4245 , A61K31/433 , A61K31/445 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K31/55 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
摘要翻译: 提供了作为趋化因子受体的有效拮抗剂的化合物。 化合物通常为芳基磺酰胺衍生物,可用于药物组合物,治疗趋化因子受体介导的疾病的方法,以及用于鉴定趋化因子拮抗剂的测定中的对照。
-
公开(公告)号:US20110118248A1
公开(公告)日:2011-05-19
申请号:US12309314
申请日:2009-01-13
申请人: Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor T. Charvat , Wei Chen , Jeff Jin , Jimmie Moore , Yibin Zeng , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew M. K. Pennell , John J. Wright , Antoni Krasinski , Qiang Wang
发明人: Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor T. Charvat , Wei Chen , Jeff Jin , Jimmie Moore , Yibin Zeng , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew M. K. Pennell , John J. Wright , Antoni Krasinski , Qiang Wang
IPC分类号: A61K31/538 , C07C311/29 , C07D213/76 , C07D401/12 , C07D401/06 , C07D413/06 , C07D405/04 , C07D471/04 , C07D417/12 , C07D498/04 , C07D401/04 , C07D413/10 , C07D401/10 , A61K31/18 , A61K31/44 , A61K31/444 , A61K31/443 , A61K31/5377 , A61K31/4375 , A61K31/4439 , A61K31/5383 , A61K31/517 , A61K31/437 , A61K31/502 , A61K31/519 , C12N5/071 , A61P9/10 , A61P9/00 , A61P25/28 , A61P29/00 , A61P3/04 , A61P3/10 , A61P13/12 , A61P1/00 , A61P11/00 , A61P37/06 , A61P35/00 , A61P25/04
CPC分类号: A61K31/5383 , A61K31/44 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/4965 , A61K31/502 , A61K31/5377 , A61K31/538 , A61K45/06 , C07C311/21 , C07D213/75 , C07D241/22 , C07D401/06 , C07D401/10 , C07D407/04 , C07D409/12 , C07D413/06 , C07D417/12 , C07D471/04 , C07D498/04
摘要: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
摘要翻译: 提供了作为CCR2受体的有效拮抗剂的化合物。 动物实验表明,这些化合物可用于治疗炎症,CCR2的标志性疾病。 化合物通常为芳基磺酰胺衍生物,并且可用于药物组合物,用于治疗CCR2介导的疾病的方法,以及用于鉴定CCR2拮抗剂的测定中的对照。
-
公开(公告)号:US08093247B2
公开(公告)日:2012-01-10
申请号:US12582001
申请日:2009-10-20
申请人: Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor T. Charvat , Wei Chen , Jeff Jin , Jimmie Moore , Yibin Zeng , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew M. K. Pennell , John J. Wright
发明人: Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor T. Charvat , Wei Chen , Jeff Jin , Jimmie Moore , Yibin Zeng , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew M. K. Pennell , John J. Wright
CPC分类号: A61K31/444 , A61K31/437 , A61K31/4439 , A61K45/06 , C07C311/21 , C07D213/75 , C07D241/22 , C07D401/06 , C07D401/10 , C07D407/04 , C07D409/12 , C07D413/06 , C07D417/12 , C07D471/04 , C07D498/04
摘要: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
摘要翻译: 提供了作为CCR2受体的有效拮抗剂的化合物。 动物实验表明,这些化合物可用于治疗炎症,CCR2的标志性疾病。 化合物通常为芳基磺酰胺衍生物,并且可用于药物组合物,用于治疗CCR2介导的疾病的方法,以及用于鉴定CCR2拮抗剂的测定中的对照。
-
公开(公告)号:US20100056509A1
公开(公告)日:2010-03-04
申请号:US12582001
申请日:2009-10-20
申请人: Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor T. Charvat , Wei Chen , Jeff Jin , Jimmie Moore , Yibin Zeng , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew M.K. Pennell , John J. Wright
发明人: Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor T. Charvat , Wei Chen , Jeff Jin , Jimmie Moore , Yibin Zeng , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew M.K. Pennell , John J. Wright
IPC分类号: A61K31/5377 , C07D471/02 , C07D401/06 , A61K31/444 , A61K31/4375 , A61K31/506 , C07D413/06 , C07D498/02
CPC分类号: A61K31/444 , A61K31/437 , A61K31/4439 , A61K45/06 , C07C311/21 , C07D213/75 , C07D241/22 , C07D401/06 , C07D401/10 , C07D407/04 , C07D409/12 , C07D413/06 , C07D417/12 , C07D471/04 , C07D498/04
摘要: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
摘要翻译: 提供了作为CCR2受体的有效拮抗剂的化合物。 动物实验表明,这些化合物可用于治疗炎症,CCR2的标志性疾病。 化合物通常为芳基磺酰胺衍生物,并且可用于药物组合物,用于治疗CCR2介导的疾病的方法,以及用于鉴定CCR2拮抗剂的测定中的对照。
-
-
-
-
-
-
-
-
-